Video

VIDEO: Public testimony gets heated at FDA panel meeting on morcellation


 

AT AN FDA ADVISORY COMMITTEE MEETING

SILVER SPRING, MD. – Power morcellation devices should be never used for gynecologic procedures, Dr. Hooman Noorchashm testified to a Food and Drug Administration expert panel on July ll.

He called out members of the FDA Obstetrics and Gynecology Devices Panel Advisory Committee by name, seeking to shame them into action to disallow power morcellation for suspected uterine fibroids.

"Is this a safe and logical device?" said Dr. Noorchashm, a cardiothoracic surgeon at Brigham and Women’s Hospital in Boston. "The only classification for this device is banned – unsafe, illogical, incorrect, and deadly."

Dr. Noorchashm’s wife, Dr. Amy Reed, had a hysterectomy with morcellation for suspected fibroids. Biopsy later confirmed sarcoma was present. Use of power morcellation caused tumor cells to spread, upstaging her sarcoma to stage IV.

dfulton@frontlinemedcom.com

On Twitter @denisefulton

Recommended Reading

ASCO: Extend adjuvant endocrine therapy to 10 years
MDedge Hematology and Oncology
VIDEO: Investigational combo stalls progression in recurrent ovarian cancer
MDedge Hematology and Oncology
Immunotherapy shows promise in metastatic cervical cancer
MDedge Hematology and Oncology
VIDEO: Immunotherapy as treatment for cervical cancer
MDedge Hematology and Oncology
VIDEO: Metastatic cervical cancer yields to immunotherapy
MDedge Hematology and Oncology
Cancer survivors have higher medical costs
MDedge Hematology and Oncology
VIDEO: Team approach is best for successful oncofertility clinic
MDedge Hematology and Oncology
Phase III trial results needed before PARP inhibitor approved for ovarian cancer indication
MDedge Hematology and Oncology
Combo olaparib/cediranib slaps down recurrent ovarian cancer
MDedge Hematology and Oncology
FDA panel addresses risks of power morcellators in fibroid surgery
MDedge Hematology and Oncology

Related Articles